Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

Thomas P. Buters, Willemijn W.A.C. van der Velden, Ismahaan Abdisalaam, Maurits S. van Maaren, Martijn B.A. van Doorn*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)3227-3229
Number of pages3
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume9
Issue number8
DOIs
Publication statusPublished - Aug 2021

Bibliographical note

Funding Information:
Conflicts of interest: Dr van Doorn reports personal fees from Leopharma, grants and personal fees from Novartis, personal fees from Abbvie, personal fees from BMS, personal fees from Celgene, personal fees from Lilly, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi-Genzyme, and personal fees from Janssen Cilag, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

Cite this